Bridging Animal and Human Models of Exercise-induced Visual Rehabilitation

Overview

This study will determine whether blood biomarker changes predict sight-saving benefits of exercise.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Basic Science
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: June 14, 2022

Detailed Description

Investigators of the Atlanta VA Center for Visual and Neurocognitive Rehabilitation (CVNR) find a very high prevalence of blinding diseases in the aging Veteran population. There are few treatments for the disorders that threaten our Veterans' eyesight. The work proposed here is the first step in determining whether exercise can be used by aging Veterans as an inexpensive and self-controlled therapy for vision loss. In order to translate exercise therapy for vision into the clinic, the investigators need to identify biomarkers that can be used to predict visual benefits. Though human and animal studies show that aerobic exercise is beneficial to specific central and peripheral nervous system functions, effects on the retina and vision were unknown until the investigators recently discovered that treadmill exercise directly protects retinal neurons in mice undergoing light-induced retinal degeneration (LIRD). The investigators found that exercise increased levels of brain-derived neurotrophic factor (BDNF) a blood protein in the blood, brain and eyes, whereas treatment of mice with a BDNF inhibitor prevented the protective effects of exercise. For this study, the investigators will assess visual outcomes and serum biomarkers (e.g, BDNF) in 60 subjects age 18-89 before, during, and after aerobic exercise. Subjects currently enrolled in a 12-week study (under IRB 56726) examining the effects of aerobic exercise on cognition will have visual testing (ERG, visual acuity, contrast sensitivity, and OCT) and blood collection prior to, during and after the standardized 12-week aerobic exercise regimen to determine whether circulating biomarker levels and visual outcomes are correlated and whether biomarker levels are altered as predicted in animal studies. This study will determine whether biomarker changes predict sight-saving benefits of exercise. As opposed to surgery or pharmacological treatments, exercise programs provide a means for Veterans to exert some control over their visual disease progression and will increase their overall health.

Interventions

  • Behavioral: Aerobic exercise
    • Stationary bicycle ergometer @ 50-80% of maximal heart rate reserve for 20 minutes to 45 minutes
  • Behavioral: Balance exercise
    • Instructor-led exercises done in a group setting for strengthening, balance, flexibility

Arms, Groups and Cohorts

  • Active Comparator: Aerobic Exercise
    • Exercise 3 times a week
  • Placebo Comparator: Balance Training
    • Group balance training 3 times a week

Clinical Trial Outcome Measures

Primary Measures

  • Visual acuity
    • Time Frame: 12 weeks
    • Early Treatment Diabetic Retinopathy Study (ETDRS) chart
  • serum BDNF
    • Time Frame: 12 weeks
    • Blood will be drawn prior to and after exercise sessions. From this, serum levels of brain derived neurotrophic factor (BDNF) will measured by immunoenzymatic assay.
  • Retinal morphology
    • Time Frame: 12 weeks
    • Scanning laser ophthalmoscopy/optical coherence tomography (SLO/OCT)
  • Contrast sensitivity
    • Time Frame: 12 weeks
    • CSV1000E Contrast Chart

Participating in This Clinical Trial

Inclusion Criteria

  • English speaking – Aged 18 to 89 – Sedentary as defined by < 120 min/week of aerobic exercise over prior 3 months – Non-demented (MMSE 24) Exclusion Criteria:

  • Severe diabetes requiring insulin – Cognitive-executive function deficit (MoCA < 26)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 89 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • VA Office of Research and Development
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Jeffrey H. Boatright, PhD, Principal Investigator, Atlanta VA Medical and Rehab Center, Decatur, GA

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.